ArticleAnnals of translational medicine2021

Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China.

Yafei Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.